THE USE OF PROSTADOZ IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA AND COEXISTENT HIGH-GRADE PROSTATIC INTRAEPITHELIAL NEOPLASIA

Introduction. In recent years there has been an increasing interest in the drug treatment of benign prostatic hyperplasia (BPH) to improve the patients’ quality of life without surgical treatment. In this connection, phytotherapeutic drugs and biologically active dietary supplements (BADS), consisting of a combination of microelements, vitamins and plant extracts, have been increasingly used in addition to synthetic preparations. Objective. To investigate the clinical effectiveness of dietary supplement ProstaDoz® in the treatment of BPH with coexistent high-grade prostatic intraepithelial neoplasia (PIN). Materials and methods. The study group comprised 30 men with BPH and high-grade PIN who were diagnosed with primary biopsy and received ProstaDoz® for three months. The control group included 18 patients with the same diagnosis who were treated with Tamsulosin. Results. After a 3-month intake of the ProstaDoz®, a statistically significant reduction was observed in symptom scores for BPH and the quality of life index by 18% (p<0.001) and 16.7% (p<0.001), respectively. The residual urine volume and total serum PSA decreased by 28.3% (p<0.001) and 46.8% (p<0.001), respectively. Unlike the control group, the rate of prostate cancer detection was 6.25 times lower in patients taking ProstaDoz®, and 16% of them had lower grade PIN compared with baseline or no PIN at all. Conclusion. The findings suggest that using ProstaDoz® in patients with BPH and high-grade PIN contributes to improving the quality of life (QoL) of patients and the regression of dysplasia.

benignprostatic hyperplasia, high-grade prostatic intraepithelial neoplasia, chemoprevention of prostate cancer, ProstaDoz